Understanding the relationships between health outcomes in generalized anxiety disorder clinical trials
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Background and Aims
The Wilson–Cleary health outcomes model is a hypothesized pathway linking traditional clinical variables to health-related quality of life (HRQL). This study tested the application of the Wilson–Cleary model to a patient population with generalized anxiety disorder (GAD) using longitudinal clinical trial data.
These secondary analyses pooled data from three similar 8-week, placebo-controlled, double-blind, randomized, multicenter trials of quetiapine XR therapy in GAD. Relevant health assessments for the model concepts included the Clinical Global Impression-Severity of Illness, Hamilton Rating Scale for Anxiety, the Pittsburgh Sleep Quality Index and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form. A lagged path model tested whether the hypothesized relationships at baseline and week 8 between the concepts of the adapted Wilson–Cleary model were consistent with the observed data.
The resulting model fit the data (RMSEA = 0.077; CFI = 0.98; NFI = 0.96) and explained 56% of the variance in overall quality of life assessment at baseline and 69% of the variance in this assessment at week 8. Moderate to strong relationships between the adjacent hypothesized concepts support the specified model.
This adapted Wilson–Cleary model for health outcomes validated in GAD should improve the understanding and usefulness of health status measurements in this condition and increase the applications of this model to other clinical trial data.
- American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press.
- Arnold, R., Ranchor, A. V., Koeter, G. H., de Jongste, M. J., & Sanderman, R. (2005). Consequences of chronic obstructive pulmonary disease and chronic heart failure: The relationship between objective and subjective health. Social Science and Medicine, 61(10), 2144–2154. CrossRef
- Astrom, A. N., & Kida, I. A. (2007). Perceived dental treatment need among older Tanzanian adults—a cross-sectional study. BMC Oral Health, 7, 9. CrossRef
- Atkinson, S., Khan, A., Joyce, M., Eggens, I., Baldytcheva, I., & Brecher, M. (2008). Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder. International Journal of Neuropsychopharmacology, 11(Suppl 1), 277.
- Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., et al. (2010). Extended-release quetiapine fumarate (quetiapine XR): A once-daily monotherapy effective in generalized anxiety disorder data from a randomized double-blind placebo- and active-controlled study. International Journal of Neuropsychopharmacology, 13(3), 305–320. CrossRef
- Barger, S. D., & Sydeman, S. J. (2005). Does generalized anxiety disorder predict coronary heart disease risk factors independently of major depressive disorder? Journal of Affective Disorders, 88(1), 87–91. CrossRef
- Bennett, S. J., Perkins, S. M., Lane, K. A., Deer, M., Brater, D. C., & Murray, M. D. (2001). Social support and health-related quality of life in chronic heart failure patients. Quality of Life Research, 10(8), 671–682. CrossRef
- Bentler, P. M., & Bonnet, D. C. (1980). Significance tests and goodness of fit in the analysis of covariance structures. Psychological Bulletin, 88(3), 588–606. CrossRef
- Buysse, D. J., Reynolds, C. F, 3rd, Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Research, 28(2), 193–213. CrossRef
- Chrischilles, E. A., Rubenstein, L. M., Voelker, M. D., Wallace, R. B., & Rodnitzky, R. L. (2002). Linking clinical variables to health-related quality of life in Parkinson’s disease. Parkinsonism & Related Disorders, 8(3), 199–209. CrossRef
- Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Earlbaum.
- Cosby, C., Holzemer, W. L., Henry, S. B., & Portillo, C. J. (2000). Hematological complications and quality of life in hospitalized AIDS patients. AIDS Patient Care STDS, 14(5), 269–279. CrossRef
- Cunningham, W. E., Crystal, S., Bozzette, S., & Hays, R. D. (2005). The association of health-related quality of life with survival among persons with HIV infection in the United States. Journal of General Internal Medicine, 20(1), 21–27. CrossRef
- Demyttenaere, K., Andersen, H. F., & Reines, E. H. (2008). Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. International Clinical Psychopharmacology, 23(5), 276–286. CrossRef
- Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacology Bulletin, 29(2), 321–326.
- Endicott, J., Rajagopalan, K., Minkwitz, M., & Macfadden, W. (2007). A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: Improvements in quality of life. International Clinical Psychopharmacology, 22(1), 29–37. CrossRef
- Endicott, J., Russell, J. M., Raskin, J., et al. (2007). Duloxetine treatment for role functioning improvement in generalized anxiety disorder: Three independent studies. The Journal of Clinical Psychiatry, 68(4), 518–524. CrossRef
- ESEMeD/MHEDEA 2000 Investigators. (2004). Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica,109(suppl 1):21–27.
- Faravelli, C., Guerrini Degl’Innocenti, B., & Giardinelli, L. (1989). Epidemiology of anxiety disorders in Florence. Acta Psychiatrica Scandinavica, 79(4), 308–312. CrossRef
- Grant, B. F., Hasin, D. S., Stinson, F. S., et al. (2005). Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychological Medicine, 35(12), 1747–1759. CrossRef
- Guy, W. (1976). Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology (pp. 218–222). Rockville, MD: National Institute for Mental Health.
- Hamilton, M. (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology, 32(1), 50–55.
- Hays, R. D., Cunningham, W. E., Sherbourne, C. D., et al. (2000). Health-related quality of life in patients with human immunodeficiency virus infection in the United States: Results from the HIV Cost and Services Utilization Study. American Journal of Medicine, 108(9), 714–722. CrossRef
- Henning, E. R., Turk, C. L., Mennin, D. S., Fresco, D. M., & Heimberg, R. G. (2007). Impairment and quality of life in individuals with generalized anxiety disorder. Depress Anxiety, 24(5), 342–349. CrossRef
- Heo, S., Moser, D. K., Riegel, B., Hall, L. A., & Christman, N. (2005). Testing a published model of health-related quality of life in heart failure. Journal of Cardiac Failure, 11(5), 372–379. CrossRef
- Hoyer, J., Becker, E. S., & Margraf, J. (2002). Generalized anxiety disorder and clinical worry episodes in young women. Psychological Medicine, 32(7), 1227–1237. CrossRef
- Hu, L. T., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling, 6(1), 1–55. CrossRef
- Jöreskog, K. G., & Sörbom, D. (2006). LISREL 8.80 for Windows [Computer Software]. Lincolnwood, IL: Scientific Software International.
- Kessler, R. C., DuPont, R. L., Berglund, P., & Wittchen, H. U. (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. American Journal of Psychiatry, 156(12), 1915–1923.
- Kessler, R. C., Keller, M. B., & Wittchen, H. (2001). The epidemiology of generalized anxiety disorder. In O. Brawman-Mintzer (Ed.), The psychiatric clinics of North America: Generalized anxiety disorder (pp. 19–40). Philadelphia: W.B. Saunders.
- Kessler, R. C., & Wittchen, H. U. (2002). Patterns and correlates of generalized anxiety disorder in community samples. Journal of Clinical Psychiatry, 63(Suppl 8), 4–10.
- Lee, D. T., Yu, D. S., Woo, J., & Thompson, D. R. (2005). Health-related quality of life in patients with congestive heart failure. European Journal of Heart Failure, 7(3), 419–422. CrossRef
- MacCallum, R. C., Browne, M. W., & Sugawara, H. M. (1996). Power analysis and determination of sample size for covariance structure modeling. Psychological Methods, 1(2), 130–149. CrossRef
- Masoudi, F. A., Rumsfeld, J. S., Havranek, E. P., et al. (2004). Age, functional capacity, and health-related quality of life in patients with heart failure. Journal of Cardiac Failure, 10(5), 368–373. CrossRef
- Massion, A. O., Warshaw, M. G., & Keller, M. B. (1993). Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. American Journal of Psychiatry, 150(4), 600–607.
- Mathisen, L., Andersen, M. H., Veenstra, M., Wahl, A. K., Hanestad, B. R., & Fosse, E. (2007). Quality of life can both influence and be an outcome of general health perceptions after heart surgery. Health Qual Life Outcomes, 5, 27. CrossRef
- Merideth, C., Cutler, A., Neijber, A., et al. (2008). Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalised anxiety disorder. European Neuropsychopharmacology, 18(suppl 4), S499. CrossRef
- Mick, E., Faraone, S. V., Spencer, T., Zhang, H. F., & Biederman, J. (2008). Assessing the validity of the Quality of Life Enjoyment, Satisfaction Questionnaire Short Form in adults with ADHD. Journal of Attention Disorders, 11(4), 504–509. CrossRef
- Norman, G., & Streiner, D. (2000). Biostatistics: The bare essentials. Toronto: Decker.
- Olsson, I., Mykletun, A., & Dahl, A. A. (2005). The Hospital Anxiety and Depression Rating Scale: A cross-sectional study of psychometrics and case finding abilities in general practice. BMC Psychiatry, 5, 46. CrossRef
- Orfila, F., Ferrer, M., Lamarca, R., Tebe, C., Domingo-Salvany, A., & Alonso, J. (2006). Gender differences in health-related quality of life among the elderly: The role of objective functional capacity and chronic conditions. Social Science and Medicine, 63(9), 2367–2380. CrossRef
- Phaladze, N. A., Human, S., Dlamini, S. B., et al. (2005). Quality of life and the concept of “living well” with HIV/AIDS in sub-Saharan Africa. Journal of Nursing Scholarship, 37(2), 120–126. CrossRef
- Revicki, D. A., Brandenburg, N., Matza, L., Hornbrook, M. C., & Feeny, D. (2008). Health-related quality of life and utilities in primary-care patients with generalized anxiety disorder. Quality of Life Research, 17(10), 1285–1294. CrossRef
- Ritsner, M., Kurs, R., Gibel, A., Ratner, Y., & Endicott, J. (2005). Validity of an abbreviated Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Quality of Life Research, 14(7), 1693–1703. CrossRef
- Sheehan, D. V., Meyers, A. L., Prakash, A., et al. (2008). The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Current Medical Research and Opinion, 24(9), 2457–2466. CrossRef
- Sousa, K. H., Holzemer, W. L., Henry, S. B., & Slaughter, R. (1999). Dimensions of health-related quality of life in persons living with HIV disease. Journal of Advanced Nursing, 29(1), 178–187. CrossRef
- Sousa, K. H., & Kwok, O. M. (2006). Putting Wilson and Cleary to the test: Analysis of a HRQOL conceptual model using structural equation modeling. Qual Life Re, 15(4), 725–737. CrossRef
- Straits-Troster, K., Fields, J. A., Wilkinson, S. B., et al. (2000). Health-related quality of life in Parkinson’s disease after pallidotomy and deep brain stimulation. Brain and Cognition, 42(3), 399–416. CrossRef
- Wettergren, L., Bjorkholm, M., Axdorph, U., & Langius-Eklof, A. (2004). Determinants of health-related quality of life in long-term survivors of Hodgkin’s lymphoma. Quality of Life Research, 13(8), 1369–1379. CrossRef
- Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65. CrossRef
- Wilson, I. B., & Cleary, P. D. (1996). Clinical predictors of functioning in persons with acquired immunodeficiency syndrome. Medical Care, 34(6), 610–623. CrossRef
- Wilson, I. B., & Cleary, P. D. (1997). Clinical predictors of declines in physical functioning in persons with AIDS: Results of a longitudinal study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 16(5), 343–349.
- Wittchen, H. U. (2002). Generalized anxiety disorder: Prevalence, burden, and cost to society. Depress Anxiety, 16(4), 162–171. CrossRef
- Wittchen, H. U., Carter, R. M., Pfister, H., Montgomery, S. A., & Kessler, R. C. (2000). Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. International Clinical Psychopharmacology, 15(6), 319–328. CrossRef
- Wyrwich, K. W., Harnam, N., Revicki, D. A., et al. (2009). Assessing health-related quality of life in generalized anxiety disorder using the Quality of Life Enjoyment and Satisfaction Questionnaire. International Clinical Psychopharmacology, 24(6), 289–295. CrossRef
- Understanding the relationships between health outcomes in generalized anxiety disorder clinical trials
Quality of Life Research
Volume 20, Issue 2 , pp 255-262
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Generalized anxiety disorder
- Wilson–Cleary model
- Health-related quality of life
- Health assessment
- Path analysis
- Lagged model
- Industry Sectors
- Author Affiliations
- 1. United BioSource Corporation, 7101 Wisconsin Ave. Suite 600, Bethesda, MD, 20814, USA
- 2. AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, USA
- 3. AstraZeneca R&D, Mölndal, Sweden